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To the Editor: With the article by Tang et al.,1 recently
published in Kidney International, we anticipate that the
lamivudine-resistant mutation and hepatitis flares will occur
in their patients with hepatitis B virus-associated membra-
nous nephropathy under further long-term lamivudine
treatment. Although, hepatitis B virus variants with muta-
tions at the YMDD motif of DNA polymerase have not been
observed in their cohort, the proportion of patients with a
documented lamivudine-resistant mutation increased from
23% in year 1 to 65% in year 5 was reported by Chayama
et al.2 and Lok et al.3
In Tang et al.’s study, there were one (8.3%), three (25%),
seven (58.3%), and one (8.3%) of 12 control patients with
hepatitis B virus-associated membranous nephropathy did
not receive lamivudine treatment went into partial remission,
complete remission, no remission, and end-stage renal
disease at 12 months, respectively. There was no patient with
remission at 12 months went to end-stage renal disease by 3
years of follow-up. It implicated that the renal function
would be conserved when patient’s proteinuria declined into
remission status. Therefore, long-term lamivudine treatment
for patients with hepatitis B virus-associated membranous
nephropathy after initial remission suggested by Tang et al.1
may not be reasonable. Although the optimal duration of
treatment and the criteria for stopping treatment have not
been established, maintenance of lamivudine therapy for 4–6
months following chemotherapy was suggested.4 We would
like to reinforce the point that one of three (33.3%) patients
with hepatitis B virus-associated membranous nephropathy
would go to remission status at 12 months under supportive
treatment in Tang et al.’s study.1 Therefore, long-term
lamivudine treatment should only be focused on patients
with no remission instead of the patients with remission at
12 months.
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